Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics. But their complex structure poses significant development and safety challenges for biopharma. In this GEN webinar, ...
TORONTO and HAIFA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company ...
Data presented at WODC USA 2026 Support Potential Application Across Multiple Indications, Including Pitt-Hopkins Syndrome, Fragile X Syndrome, and Rett Syndrome Restoration of Cognitive and ...
As drug developers pursue increasingly complex therapies, traditional bioanalytical approaches are being put to the test. How ...
This Brush Up is sponsored by MilliporeSigma. Learn more about therapeutic synthesis pathways. Drug development is a process that spans many years, from the initial phase of identifying potential drug ...
JW Pharmaceutical has announced its preclinical findings and global development strategy for DDC-02, a therapeutic candidate for rare neurodevelopmental disorders, at the World Orphan Drug Congress ...
SEOUL, South Korea, June 11, 2026--(BUSINESS WIRE)--JW Pharmaceutical (KRX:001060) presented preclinical findings and its global development strategy for DDC-02, a therapeutic candidate for rare ...
JW Pharmaceutical (KRX:001060) presented preclinical findings and its global development strategy for DDC-02, a therapeutic candidate for rare neurodevelopmental disorders, at the World Orphan Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results